Drug Profile
NP 137
Alternative Names: Anti-netrin-1; NP-137; NP137P; NP137RLatest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Netris Pharma
- Developer Centre Leon Berard; Merck Sharp & Dohme; Netris Pharma; University Hospital Grenoble
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Acute myeloid leukaemia; Cervical cancer; Endometrial cancer
- Phase I Liver cancer; Pancreatic cancer
- Research Unspecified
Most Recent Events
- 12 Jan 2024 NETRIS Pharma plans a phase I trial for Pancreatic cancer (First-line therapy, Neoadjuvant therapy, Combination therapy) in the US (IV) (NCT06203821)
- 04 Dec 2023 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, Refractory metastatic disease, Second-line therapy or greater, In the elderly) in France (IV) (NCT06150040)
- 29 Nov 2023 NETRIS Pharma plans a phase I/II trial for Acute myeloid leukemia (Combination therapy, Second-line therapy or greater, In the elderly) in France (IV) in December 2023, (NCT06150040)